Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-16

  Degl'Innocenti, Debora ^a   Alberti, Chiara ^a   Castellano, Giancarlo ^a   Greco, Angela ^a   Miranda, Claudia ^a   Pierotti, Marco A ^a   Seregni, Ettore ^a   Borrello, Maria Grazia ^a   Canevari, Silvana ^a   Tomassetti, Antonella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; SIGNAL TRANSDUCTION; THYROID CELL; THYROID PAPILLARY CARCINOMA;

EID: 77958509191     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012701     Document Type: Article

References (40)

1. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
2. Middendorp M, Grunwald F (2010) Update on recent developments in the therapy of differentiated thyroid cancer. Semin Nucl Med 40: 145-152.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638-2648.
4. Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8: 83-95.
5. Greco A, Borrello MG, Miranda C, Degl'Innocenti D, Pierotti MA (2009) Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 53: 440-453.
6. Borrello MG, Alberti L, Fischer A, Degl'Innocenti D, Ferrario C, et al. (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 102: 14825-14830.
7. Handkiewicz-Junak D, Czarniecka A, Jarzab B (2010) Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 322: 8-28.
8. Frattini M, Ferrario C, Bressan P, Balestra D, De CL, et al. (2004) Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23: 7436-7440.
9. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656.
10. Graeber TG, Eisenberg D (2001) Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles. Nat Genet 29: 295-300.
11. Castellano G, Reid JF, Alberti P, Carcangiu ML, Tomassetti A, et al. (2006) New Potential Ligand-Receptor Signaling Loops in Ovarian Cancer Identified in Multiple Gene Expression Studies. Cancer Res 66: 10709-10719.
12. Ulisse S, Baldini E, Toller M, Marchioni E, Giacomelli L, et al. (2006) Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer 42: 2631-2638.
13. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, et al. (2005) Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90: 5270-5278.
14. Lemoine NR, Mayall ES, Jones T, Sheer D, McDermid S, et al. (1989) Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection. Br J Cancer 60: 897-903.
15. Schneider MR, Wolf E (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218: 460-466.
16. Madshus IH, Stang E (2009) Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J Cell Sci 122: 3433-3439.
17. Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 41: 107-127.
18. Bernard DJ, Chapman SC, Woodruff TK (2001) Mechanisms of inhibin signal transduction. Recent Prog Horm Res 56: 417-450.
19. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, et al. (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11: R24.
20. Castellone MD, Carlomagno F, Salvatore G, Santoro M (2008) Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 22: 1023-1038.
21. Castellone MD, Guarino V, De FV, Carlomagno F, Basolo F, et al. (2004) Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 23: 5958-5967.
22. Gorgoulis V, Aninos D, Priftis C, Evagelopoulou C, Karameris A, et al. (1992) Expression of epidermal growth factor, transforming growth factor-a and epidermal growth factor receptor in thyroid tumors. In Vivo 6: 291-296.
23. Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, et al. (1996) EGF-receptors in human normal and pathological thyroid tissue. Histopathology 28: 221-227.
24. Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR (1993) Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int J Cancer 55: 37-43.
25. Griffith OL, Melck A, Jones SJ, Wiseman SM (2006) Meta-analysis and metareview of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 24: 5043-5051.
26. Delys L, Detours V, Franc B, Thomas G, Bogdanova T, et al. (2007) Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 26: 7894-7903.
27. Smalley KS, Nathanson KL, Flaherty KT (2009) Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 69: 3241-3244.
28. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, et al. (2008) RET/PTCinduced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res 68: 4183-4191.
29. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, et al. (2008) A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18: 317-323.
30. Tosi E, Valota O, Negri DRM, Adobati E, Mazzoni A, et al. (1995) Anti-tumor efficacy of an anti-epidermal growth factor receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int J Cancer 62: 643-650.
31. Tohyama K, Yoshida Y, Ohashi K, Sano E, Kobayashi H, et al. (1992) Production of multiple growth factors by a newly established human thyroid carcinoma cell line. Jpn J Cancer Res 83: 153-158.
32. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341.
33. Tomassetti A, Mangiarotti F, Mazzi M, Sforzini S, Miotti S, et al. (2003) The Variant Hepatocyte Nuclear Factor 1 Activates the P1 Promoter of the Human alpha-Folate Receptor Gene in Ovarian Carcinoma. Cancer Res 63: 696-704.
34. Sanna E, Miotti S, Mazzi M, De Santis G, Canevari S, et al. (2007) Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Exp Cell Res 313: 1307-1317.
35. De Santis G, Miotti S, Mazzi M, Canevari S, Tomassetti A (2009) E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene 28: 1206-1217.
36. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De PG, et al. (2009) RET/ PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 11: 10-21.
37. Vasko V, Espinosa AV, Scouten W, He H, Auer H, et al. (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104: 2803-2808.
38. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, et al. (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1587-1597.
39. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, et al. (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22: 3531-3539.
40. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, et al. (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98: 15044-15049.